Transitioning to Clinical Use
OrthoPreserve was awarded an NIH Small Business Innovation Research grant to advance the development of our meniscus implant technology in September 2023. This grant allowed us to complete animal studies and develop a minimally invasive surgical technique.
We expect our currently open round of fundraising will allow us to execute the remaining testing required by the FDA to initiate clinical trials.
OrthoPreserve’s meniscus implant was granted FDA Breakthrough Device Designation in December 2024. This endorsement highlights the significant need that exists for our technology and the promise it holds for the future of patient care, and allows for a more efficient path to approval and patient use.